Role of sleep-disordered breathing and sleep-wake disturbances for stroke and stroke recovery

ABSTRACT

Background: Sleep-disordered breathing (SDB) and sleep-wake disturbances (SWD) are highly prevalent in stroke patients. Recent studies suggest that they represent both a risk factor and a consequence of stroke and affect stroke recovery, outcome, and recurrence.

Methods: Review of literature.

Results: Several studies have proven SDB to represent an independent risk factor for stroke. Sleep studies in TIA and stroke patients are recommended in view of the very high prevalence (>50%) of SDB (Class IIb, level of evidence B). Treatment of obstructive SDB with continuous positive airway pressure is recommended given the strength of the increasing evidence in support of a positive effect on outcome (Class IIb, level of evidence B). Oxygen, biphasic positive airway pressure, and adaptive servoventilation may be considered in patients with central SDB. Recently, both reduced and increased sleep duration, as well as hypersomnia, insomnia, and restless legs syndrome (RLS), were also suggested to increase stroke risk. Mainly experimental studies found that SWD may in addition impair neuroplasticity processes and functional stroke recovery. Treatment of SWD with hypnotics and sedative antidepressants (insomnia), activating antidepressants or stimulants (hypersomnia), dopaminergic drugs (RLS), and clonazepam (parasomnias) are based on single case observations and should be used with caution.

Conclusions: SDB and SWD increase the risk of stroke in the general population and affect short- and long-term stroke recovery and outcome. Current knowledge supports the systematic implementation of clinical procedures for the diagnosis and treatment of poststroke SDB and SWD on stroke units.

GLOSSARY

AHI = apnea-hypopnea index; BMI = body mass index; CHD = coronary heart disease; CI = confidence interval; CPAP = continuous positive airway pressure; CSA = central sleep apnea; CSB = Cheyne-Stokes breathing; EDS = excessive daytime sleepiness; HR = hazard ratio; NREM = non-REM; OR = odds ratio; OSA = obstructive sleep apnea; PLMS = periodic limb movements during sleep; RBD = REM sleep behavior disorder; RLS = restless legs syndrome; SDB = sleep-disordered breathing; SWA = slow wave activity; SWD = sleep-wake disturbances.

Sleep-disordered breathing (SDB) and sleep-wake disturbances (SWD) are highly prevalent in neurologic diseases, influencing their incidence, course, and outcome, which has been linked to sleep having neurorestorative functions. In this review, we review the data suggesting that sleep-wake disorders represent both a risk factor and a consequence of stroke that modulate stroke recovery and outcome. For this purpose, we performed a comprehensive PubMed search in December 2015 with the terms sleep or sleepiness or insomnia or hypersomnia or restless legs syndrome or periodic limb movements during sleep and stroke that achieved 2,691 hits. Articles were selected based on their contribution to our current understanding of sleep/stroke links. Systematic reviews and meta-analyses were extensively used to evaluate research evidence. Diagnostic challenges and treatment recommendations are presented.
DISTURBED SLEEP IN STROKE PATIENTS

Sleep-disordered breathing. In a meta-analysis of 29 studies with 2,343 ischemic or hemorrhagic stroke or TIA patients, 72%, 63%, or 38% revealed SDB defined by an apnea-hypopnea index (AHI) >5/h, >10/h, or >20/h. SDB was most severe in acute stroke and improved during stroke recovery. Fifty-three percent of patients still exhibited an AHI >10/h after 4 weeks. SDB was similarly prevalent in stroke and TIA, indicating that SDB mostly represents a preexisting condition. In a cross-sectional study on 335 acute stroke or TIA patients, SDB was associated with wake-up stroke, when accompanied by cardiac right-to-left shunts, indicating that SDB may provoke paradoxical embolism. Initial studies found no link between SDB and stroke topography. Population-based and clinical cohorts recently noted an association of SDB with brainstem stroke, suggesting that lower cranial nerve dysfunction aggravates SDB. The most common form of SDB is obstructive sleep apnea (OSA), which is caused by cessation of nasal flow due to upper airway collapse. Not rarely, stroke patients reveal combinations of OSA and central types of SDB; that is, central sleep apnea (CSA) and Cheyne-Stokes breathing (CSB).

CSA is characterized by cyclic fluctuations in breathing drive and hyperpneas alternating with apneas or hypopneas. CSA/CSB was first described in bilateral stroke associated with disturbed consciousness or heart failure. Heart failure is associated with nocturnal rostral fluid shifts decreasing leg volume and increasing neck circumference, which predisposes to upper airway collapse. More recently, CSA during sleep was found in unilateral stroke with preserved consciousness without overt heart failure. CSA/CSB in acute stroke was linked to occult cardiac dysfunction or disruption of the central autonomic networks. CSA/CSB improves in the subacute stroke phase. In chronic stroke, CSA/CSB is strongly associated with heart failure.

Hypersomnia/excessive sleep/excessive daytime sleepiness (EDS). Hypersomnia, i.e., increased sleep, is mostly found after subcortical and pontomesencephalic stroke. In 285 consecutive patients evaluated after 21 ± 18 months, hypersomnia (27% of patients with sleep needs ≥10 h/d), EDS (28% with Epworth Sleepiness Scale score ≥10) and fatigue (46% with Fatigue Severity Scale score ≥4.0) were frequent. Although hypersomnia improves during the first months poststroke, fatigue can persist for years. The most dramatic form of poststroke hypersomnia is noted after paramedian thalamic stroke. Initially, patients exhibit severe hypersomnia and sleep-like behavior during up to 20 h/d, associated with attention, cognition, and memory deficits. Hypersomnia improves within months, whereas cognitive deficits often persist, particularly after left-sided and bilateral stroke. Patients with bilateral stroke may report increased sleep needs for years.

Insomnia/reduced sleep. Insomnia, i.e., difficulty in falling and staying asleep, is highly prevalent in stroke patients. During the first months poststroke, insomnia prevalence may be as high as ~50%. One third of insomnia appear de novo; two thirds of patients have insomnia already before stroke. Poststroke insomnia often results from environmental factors (light, noise on stroke units) or comorbidities (SDB, depression, pain). Less commonly, insomnia may be directly related to brain damage. Near-complete loss of sleep was reported after pontomesencephalic stroke. In paramedian thalamic stroke, insomnia may reflect the absence of sleep spindles. In military veterans with penetrating brain injury, insomnia was associated with left dorsomedial prefrontal cortex damage.

Restless legs syndrome (RLS)/periodic limb movements during sleep (PLMS). In 2 series of 96 or 137 patients examined within 15 days or at 1 month poststroke, 12% or 13% fulfilled RLS criteria, i.e., urge for limb movements that improves with activity and worsens in the evenings and nights and at rest. Two thirds of patients had bilateral RLS symptoms; one third had unilateral symptoms contralateral to the stroke. RLS was frequently accompanied by PLMS, i.e., involuntary periodic limb movements during non-REM (NREM) sleep. Patients exhibiting RLS exhibited a higher neck circumference and higher diabetes prevalence than patients without RLS. Sleep quality was reduced in these patients. PLMS are even more prevalent than RLS in stroke patients. In a case-control study of 35 patients with acute supratentorial ischemic stroke, a PLMS index >5/h was found in 77% of stroke patients but only 29% of age- and sex-matched controls. PLMS were contralateral to the stroke in 70% and bilateral in 30%.

REM sleep behavior disorder (RBD). In RBD, patients act out dreams, exhibiting loss of atonia and increased phasic muscle activity during REM sleep. Following early RBD observations in patients with brainstem infarcts, a recent assessment on 119 ischemic stroke patients estimated the RBD prevalence as ~11%. Forty-six percent of patients with RBD had brainstem infarcts.

DISTURBED SLEEP AS STROKE RISK FACTOR

Sleep-disordered breathing. Following a seminal study on 1,022 patients admitted to a sleep laboratory, which reported an association of SDB defined as AHI ≥5/h with incident stroke, TIA, and death over 6 years follow-up after adjustment for vascular risk factors, 4 population-based studies evaluated the predictive value of SDB for stroke risk:

© 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
1. The Wisconsin sleep cohort study included 1,475 participants. SDB defined by AHI ≥20/h was associated in a cross-sectional analysis with history of stroke after adjustment for age, sex, and vascular risk factors (odds ratio [OR] 4.33; confidence interval [CI] 1.32–14.24). In a longitudinal analysis including 1,189 participants, 22 incident first-ever strokes were noted over 4 years. SDB predicted stroke in a univariate regression. After adjustment for age, sex, and body mass index (BMI), this association was no longer significant.

2. In the Vitoria Sleep Project, 394 noninstitutionalized stroke-free participants >70 years were followed up over 6 years (incident 20 strokes). SDB defined by AHI ≥30/h predicted stroke in a regression adjusted for sex (hazard ratio [HR] 2.52; CI 1.04–6.01). Due to limited statistical power, age and vascular risk factors could not be adjusted for.

3. The Sleep Heart Health Study was a population-based cohort of 5,422 participants ≥40 years followed up over 8.7 years. A total of 193 strokes occurred. OSA predicted ischemic stroke in multivariable regressions adjusted for age, sex, and vascular risk factors in men (HR [4th vs 1st AHI quartile] 2.86; CI 1.10–7.39) but not in women (HR 1.21; CI 0.65–2.24).

4. In a nationwide survey among 4.5 million Danish citizens, 33,274 participants developed sleep apnea over 11 years (mean age 53 years; 79% men), of whom 44% received persistent continuous positive airway pressure (CPAP) therapy. A total of 150,294 ischemic strokes occurred. Sleep apnea predicted ischemic stroke after adjustment for age, sex, and vascular risk factors (HR 1.23; CI 1.11–1.36). This effect was specifically noted in participants <50 years (HR 1.80; CI 1.36–2.39).

A meta-analysis of prospective clinical and population-based studies concluded that SDB is an independent stroke predictor (OR 2.24; CI 1.57–3.19). Stroke risk increased with AHI. The meta-analysis stated that evidence was sparse in women. Most recently, a Taiwanese group evaluated sex-related consequences of SDB in a large cohort of 29,961 participants with SDB who were compared with 119,844 age- and sex-matched controls without SDB. Over a follow-up of up to 14 years, stroke incidence was increased in both sexes, notably more strongly in women than men (HR 1.44 [CI 1.20–1.72] and HR 1.21 [CI 1.01–1.24], respectively, after adjustment for age and vascular risk factors). Interestingly, stroke incidence was increased most strongly in young women ≤35 years (HR 4.90 [CI 1.93–12.40]).

The mechanisms underlying the elevated stroke risk in SDB patients have been summarized previously. Recurrent hypoxia in OSA is accompanied by intrathoracic pressure changes, sympathetic activation, and blood pressure swings, which via oxidative stress, endothelial dysfunction, and inflammation predispose to drug-resistant arterial hypertension, atherosclerosis, cardiac arrhythmia, hypercoagulation, heart failure, and paradoxical embolisms. CPAP therapy attenuates these consequences.

**Hypersomnia/excessive sleep/EDS.** A meta-analysis of 11 community-representative studies with 559,252 participants and 11,695 stroke events revealed that long sleep, mostly defined as ≥8–9 hours sleep/night in questionnaires, is an independent predictor of incident stroke after adjustment for age, sex, vascular risk factors, and comorbidities (HR 1.45; CI 1.30–1.62). In 2 population-based studies involving 9,095 participants who were followed up over 5.1 years each (in total 208 incident strokes), significant (Epworth Sleepiness Scale ≥10/24) or frequent EDS predicted stroke after adjustment for age, sex, vascular risk factors, and comorbidities (HR 3.00; CI 1.57–5.73, and HR 2.10; CI 1.13–3.89, respectively). In a cross-sectional analysis within one of these studies, which included 1,244 stroke-free participants receiving MRI, long sleep was associated with subcortical white matter hyperintensities, suggesting that excessive sleep may result from cerebral small vessel disease, reflecting markers of subclinical atherosclerosis.

**Insomnia/reduced sleep.** After earlier inconsistent studies, a recent meta-analysis found that short sleep, mostly defined as ≤5–6 hours sleep/night in questionnaires, is an independent predictor of incident stroke after adjustment for age, sex, vascular risk factors, and comorbidities, albeit with lower HR than long sleep (1.15; CI 1.07–1.24). Stroke risk might depend on the presence of clinical sleep complaints. In 2 population-representative case-control studies including 21,438 and 22,040 insomniacs, which were followed up over 4 or 10 years, respectively (1,545 and 1,049 incident strokes), physician-diagnosed insomnia predicted stroke after adjustment for age, sex, vascular risk factors, and comorbidities, albeit with lower HR than long sleep (1.15; CI 1.07–1.24). Stroke risk might depend on the presence of clinical sleep complaints. In 2 population-representative case-control studies including 21,438 and 22,040 insomniacs, which were followed up over 4 or 10 years, respectively (1,545 and 1,049 incident strokes), physician-diagnosed insomnia predicted stroke after adjustment for age, sex, vascular risk factors, and comorbidities, albeit with lower HR than long sleep (1.15; CI 1.07–1.24).
RLS/PLMS. After inconsistent findings from cross-sectional studies regarding the association of RLS with stroke and coronary heart disease (CHD), longitudinal studies in population-based cohorts and health professionals reported that RLS at baseline predicts incident CHD and death, but not stroke, in addition to age, sex, and vascular risk factors. In the 2 stroke studies, 54,558 participants were followed up over 2.1–7.3 years (673 incident strokes).

In 2 population-representative cohorts including 5,620 and 7,392 participants who were followed up over up to 8.1 years, vascular risk factors, namely arterial hypertension, diabetes, hypercholesterolemia, and BMI, predicted incident RLS. In the larger of these studies, incident RLS predicted incident stroke, which in this study was noted in 397 participants. The combined evidence of these studies is still insufficient for justifying final conclusions about mutual links between RLS and stroke.

In 1,093 patients with end-stage renal disease, which carries a particularly high vascular risk, RLS predicted stroke over a 3.7-year follow-up after adjustment for age, sex, and vascular risk factors (HR 2.64; 1.49–4.91). It has been suggested that RLS consequences depend on the duration of RLS complaints. In the largest CHD study, comprising 70,977 participants with 5.6 years of follow-up, RLS predicted CHD when RLS complaints persisted for ≥3 years. RLS-associated PLMS are accompanied by short-lasting elevations of blood pressure and sympathetic hyperactivity. Whether these autonomic responses are able to induce arterial hypertension remains to be shown.

DISTURBED SLEEP AND STROKE RECOVERY AND OUTCOME Sleep-disordered breathing. In a systematic review, 10 studies including 1,203 stroke and TIA patients were identified, in which effects of SDB on stroke outcome, i.e., death and recurrent vascular events, were analyzed. All studies reported elevated risks for death or vascular events, respectively. Most studies had follow-ups ≤2 years. Only 2 studies evaluating cohorts of 132 and 166 patients with 10 or 7 years follow-up (116 and 89 deaths, respectively) were truly powered for multivariable regression analyses. In these studies, OSA, defined by AHI ≥15/h or AHI ≥20/h, predicted death (HR 1.76; 1.05–2.95) or nonfatal cardiovascular events (namely recurrent stroke) (HR 1.76; 1.12–2.68) in addition to age, sex, vascular risk factors, and Barthel Index. Earlier smaller studies reported that SDB negatively affects poststroke arterial blood pressure, early neurologic recovery, and hospitalization duration. These studies were not powered for multivariable analyses.

Hyersomnia/excessive sleep/EDS. Hypersomnia/EDS impairs stroke recovery, as shown in a cohort of 213 stroke patients admitted to an acute rehabilitation unit, in which hypersomnia detected by rehabilitation therapists predicted disability and nursing home referral at discharge. In a nationwide register of 8,194 stroke patients, the presence of fatigue 2 years poststroke was associated with nursing home referral and predicted mortality in the following year (297 deaths) after adjustment for age, sex, stroke type, and activities of daily living. This study did not adjust for medical conditions unrelated to the stroke (e.g., infections, cardiovascular diseases).

Insomnia/reduced sleep. In acute stroke patients, insomnia assessed by questionnaires was associated with poor life satisfaction in addition to depression and severe stroke. In experimental stroke models, sleep loss/deprivation was found to augment brain injury and impair neuroplasticity, whereas drugs that promote NREM and REM sleep had a favorable effect on neuroplasticity and stroke recovery. In 13 chronic stroke patients, imitation-based speech therapy increased slow wave activity (SWA) during sleep evaluated by high-density EEG. SWA in speech-related areas correlated closely with improvements of aphasia scores. These data argue in favor of a sustained role of NREM sleep in stroke recovery.

RLS/PLMS. In 96 acute stroke patients followed up over 1 year, patients with RLS (12.5%) had a higher neck circumference, poorer sleep quality, and higher diabetes prevalence than patients without RLS. Stroke recovery evaluated by the modified Rankin Scale and Barthel Index was worse in RLS than non-RLS patients after adjustment for diabetes and BMI. Due to the limited size of this study, other risk factors could not be adjusted for.

DIAGNOSIS AND THERAPY Sleep-disordered breathing. SDB can be accurately diagnosed in stroke patients by respiratory polygraphy, in which nasal airflow, respiratory movements, and capillary oxygen saturation are monitored. More simple but less accurate screening methods are oximetry or nasal airflow measurement, which can be combined with SDB questionnaires (e.g., Berlin questionnaire). CPAP is the treatment of choice for OSA. In patients with CSA/CSB, oxygen, biphasic positive airway pressure, or adaptive servoventilation may be considered. Mechanical ventilation and rarely tracheostomy may become necessary in patients with central hyperventilation.

Eight randomized studies investigated effects of CPAP poststroke (table 1), of which 5 initiated in the acute stroke phase, i.e., the first week poststroke. Most studies noted acceptable CPAP
<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Patients</th>
<th>Age, y</th>
<th>BMI, kg/m²</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandberg et al.⁴³</td>
<td>Randomized single-blind study</td>
<td>63 ischemic stroke patients with respiratory disturbance index ≥ 15/h recruited in a rehabilitation unit at 2–4 weeks poststroke; randomization to CPAP or no CPAP over 28 days</td>
<td>77 ± 8 (no CPAP), 78 ± 6 (CPAP)</td>
<td>25 ± 5 (no CPAP), 24 ± 4 (CPAP)</td>
<td>CPAP was used by 31 of 33 patients for 4 weeks; mean CPAP use was 4.1 ± 3.6 h/night; CPAP treatment improved depressive symptoms, but did not significantly change MMSE score or Barthel index; low cognitive level (MMSE score) predicted poor CPAP use</td>
</tr>
<tr>
<td>Hsu et al.⁴⁴</td>
<td>Randomized single-blind study (blind assessment of outcomes)</td>
<td>30 stroke patients with AHI ≥ 30/h recruited at 21–25 days poststroke; randomization to CPAP or no CPAP over 8 weeks</td>
<td>Median 73 (Q1, Q3: 73, 81) (no CPAP), 74 (Q1, Q3: 65, 77) (CPAP)</td>
<td>Median 25 (Q1, Q3: 21, 29) (no CPAP), 27 (Q1, Q3: 22, 33) (CPAP)</td>
<td>Mean CPAP use was poor (1.4 h/night); the study was prematurely stopped due to poor recruitment; CPAP treatment did not influence neurologic outcome, anxiety, depression, or quality of life; no significant difference in 24-hour daytime and nighttime systolic, diastolic, and mean arterial blood pressure between groups; 7 of 15 patients (47%) kept using the CPAP device over more than 4 weeks; treatment discontinued in 8 patients because of problems with mask or machine, stroke-related confusional states, or upper airway symptoms; CPAP use positively correlated with good Barthel index and good language capabilities</td>
</tr>
<tr>
<td>Bravata et al.⁴⁵</td>
<td>Randomized single-blind study</td>
<td>70 TIA patients randomized within 72 hours post-TIA; patients with AHI ≥ 5/h received CPAP or no CPAP over 90 days; 12 patients (no CPAP) vs 30 patients (CPAP) completed study</td>
<td>67 ± 13 (no CPAP), 66 ± 12 (CPAP)</td>
<td>28 ± 7 (no CPAP), 29 ± 4 (CPAP)</td>
<td>Forty percent of SDB patients had acceptable (≥ 4 h/night) and 60% some (≤ 4 h/night) CPAP use; 3 CPAP patients and 1 control patient had recurrent vascular events; there was a nonsignificant tendency towards a lower event rate in patients with acceptable (0%) compared with some (8%) CPAP use (p = 0.08)</td>
</tr>
<tr>
<td>Svatikova et al.⁴⁶</td>
<td>Randomized single-blind cross-over study</td>
<td>In first study phase, 18 ischemic stroke patients with AHI ≥ 5/h randomized to positional therapy (therapeutic pillow) or no positional therapy (regular pillow) within 14 days poststroke; treatment administered during 2 consecutive nights in crossover design; in second study phase, same 18 patients randomized to positional therapy or no positional therapy for 3 months</td>
<td>Median 58 (Q1, Q3: 54, 68)</td>
<td>Median 29 (Q1, Q3: 28, 33)</td>
<td>in-within participant comparison (first phase), positional therapy reduced AHI from median 139/h (21 h, 54/h) to 27/h (22/h, 47/h); therapeutic pillow reduced time supine from median 142 (11, 298) to 30 (3, 66) minutes; median and minimum oxygen saturation remained unchanged; in second phase (between-participant comparison), self-reported adherence was 3 (33%) all nights, 1 (11%) most nights, 2 (22%) some nights, and 3 (33%) no nights in participants randomized to positional therapy; of those randomized to the therapeutic pillow, 7 (78%) had a good outcome, while 6 (67%) of those not randomized to the pillow had a good outcome</td>
</tr>
<tr>
<td>Ryan et al.⁴⁷</td>
<td>Randomized single-blind study (blind assessment of outcomes)</td>
<td>44 stroke patients with AHI ≥ 15/h recruited within 3 weeks poststroke; randomization to CPAP or no CPAP over 4 weeks</td>
<td>61 ± 10 (no CPAP), 63 ± 13 (CPAP)</td>
<td>29 ± 5 (no CPAP), 27 ± 6 (CPAP)</td>
<td>Mean CPAP use was 5.0 ± 2.3 h/night; regarding primary outcomes, CPAP treatment improved neurologic deficits evaluated by Canadian Neurologic Scale, but not 6-minute walk distance, sustained attention response, and digit and visual spatial span; regarding secondary outcomes, CPAP improved sleepiness evaluated by Epworth Sleepiness Scale, motor component of the functional independence measure, Chedoke-McMaster lower leg function, and affective component of depression</td>
</tr>
<tr>
<td>Bravata et al.⁴⁸</td>
<td>Randomized single-blind study</td>
<td>55 ischemic stroke patients randomized within 72 hours poststroke; patients with AHI ≥ 5/h received CPAP or no CPAP over 30 days; 15 patients (no CPAP) vs 16 patients (CPAP) completed study</td>
<td>72 ± 13 (no CPAP), 71 ± 9 (CPAP)</td>
<td>29 ± 7 (no CPAP), 27 ± 4 (CPAP)</td>
<td>A total of 62.5% of SDB patients had acceptable (≥ 4 h/night) and 37.5% some (≤ 4 h/night) CPAP use; NIH Stroke Scale improved more in CPAP (− 3.0) than control (− 1.0) patients (p = 0.03); 1 CPAP patient and 3 control patients had recurrent vascular events; event rate did not differ between groups</td>
</tr>
<tr>
<td>Parra et al.⁴⁹</td>
<td>Randomized single-blind study</td>
<td>140 ischemic stroke patients with AHI ≥ 20/h recruited within 3–6 days poststroke; randomization to CPAP or no CPAP over 5 years</td>
<td>66 ± 9 (no CPAP), 64 ± 9 (CPAP)</td>
<td>29 ± 4 (no CPAP), 30 ± 5 (CPAP)</td>
<td>Of 71 patients randomized to CPAP, 14 refused participation after 1–3 nights and 6 additional patients refused continuation after a mean of 10 months; in the others, mean CPAP use was 5.3 ± 1.9 h/night; percentage of patients exhibiting improvement in Canadian neurologic scale and Rankin scale 1 month after stroke was significantly higher in patients receiving CPAP than controls; mean values in Canadian neurologic scale and Rankin scale did not differ between groups at any timepoint; in log rank tests, CPAP increased cardiovascular survival (100% vs 89.9%; p = 0.02); there was a nonsignificant tendency towards increased cardiovascular event-free survival in CPAP compared with control patients (89.5% vs 75.4%; p = 0.06)</td>
</tr>
</tbody>
</table>
adherence (≥4 h/night) in more than half of the patients. Two studies (one acute, one postacute) reported poor CPAP use (0.6–1.4 h/night). Seven studies used no CPAP as control condition. One study used sham CPAP; this study was truly double-blind. Despite the small study size (a total of 484 patients were included), 4 of 8 studies reported favorable CPAP effects, namely significant improvements in neurologic recovery, sleepiness, depression, and recurrent vascular events. One study found a nonsignificant tendency towards better neurologic improvement in patients receiving CPAP. The remaining studies reported no significant outcome changes, but beneficial associations of CPAP use with at least some aspects of daytime wakefulness, neurologic recovery, or low recurrent vascular event rates.

These findings contrast with the multitude of negative pharmacologic stroke studies. However, some CPAP studies were designed as feasibility studies. These studies were not powered for demonstrating outcome changes. In several studies, primary outcomes were not predefined. Larger multicenter studies with predefined outcomes, e.g., Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy (SAS-CARE) (https://www.clinicaltrials.gov/ct2/show/NCT01097967), are ongoing. Their results are eagerly awaited.

A small percentage of stroke patients worldwide receive CPAP treatment. Yet the American Heart Association recently included recommendations on diagnosis and treatment of SDB, stating that (1) a sleep study might be considered for patients with ischemic stroke or TIA on the basis of the very high prevalence of sleep apnea in this population and (2) CPAP treatment might be considered for patients with ischemic stroke and TIA and sleep apnea, given the emerging evidence in support of improved outcomes (Class IIb evidence, B recommendation).

In a crossover study on 18 ischemic stroke patients with AHI >5/h randomized to positional therapy (therapeutic pillow) or no positional therapy within 14 days poststroke, positional therapy reduced AHI46 (Class III evidence; tables 1 and 2). Median and minimum oxygen saturation remained unchanged.

In an observation study on 10 ischemic stroke patients with AHI >15/h not eligible for CPAP at 4.8 ± 3.7 days poststroke, transnasal insufflation with high-flow air (18 L/min) moderately reduced AHI from 40.7/h to 31.0/h and increased slow wave sleep. In 15 ischemic stroke patients with predominant CSA not adherent to CPAP at 11 months poststroke, adaptive servoventilation reduced EDS. Until further studies become available, adaptive servoventilation should be used with caution, since increased mortality has been reported during adaptive servoventilation in SDB patients with systolic heart failure.

Weight loss should improve SDB, but was not systematically examined. Patient handling should always include prevention and therapy of secondary complications (respiratory infections, pain) and cautious use of alcohol and sedative-hypnotic drugs, which negatively affect breathing during sleep. In stroke patients with SDB, severe motor deficits (specifically facial/bulbar palsy), cognitive deficits, aphasia, and depression may represent factors compromising CPAP compliance.

### Table 1

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Patients</th>
<th>Age, y</th>
<th>BMI, kg/m²</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minnerup et al.50</td>
<td>Randomized single-blind study</td>
<td>50 ischemic stroke patients with AHI &gt;10/h recruited within 1st night poststroke; randomization to CPAP or no CPAP over 7 days</td>
<td>63 ± 11 (no CPAP), 69 ± 10 (CPAP)</td>
<td>Forty percent of SDB patients had acceptable (≥4 h/night), 56% some (≥4 h/night), and 4% no CPAP use; patients receiving CPAP revealed a nonsignificant tendency towards a better NIH Stroke Scale improvement (−2.0) compared with control patients (−1.4, p = 0.09)</td>
<td></td>
</tr>
<tr>
<td>Brown et al.51</td>
<td>Randomized double-blind study</td>
<td>32 ischemic stroke patients with AHI ≥5/h recruited within 7 days poststroke, randomization to CPAP or sham CPAP over 90 days</td>
<td>Median 74 (Q1, Q3: 55, 81) (sham CPAP), 61 (46, 76) (CPAP)</td>
<td>Median 29 (Q1, Q3: 16, 39) (sham CPAP), 28 (16, 39) (CPAP)</td>
<td>Of 15 patients who commenced active CPAP titration, 11 (73%) took the device home and 8 (53%) completed the 90-day follow-up; of 17 participants who commenced sham titration, 11 (65%) took the sham device home and completed the 90-day follow-up; cumulative usage was poor (mean 0.8 h/night for sham CPAP, 0.6 h/night for CPAP); average usage on days used was 3.5 (1.8, 4.1) h/night for sham CPAP, 4.5 (2.8, 5.5) h/night for CPAP; 50% of patients receiving sham CPAP felt more awake during the day; stroke outcome evaluated by Barthel Index, Rankin scale, and NIH Stroke Scale remained unchanged</td>
</tr>
</tbody>
</table>

Abbreviations: AHI – apnea-hypopnea index; BMI – body mass index; MMSE – Mini-Mental State Examination. If not otherwise mentioned, data are mean ± SD.
Hypersomnia/excessive sleep/EDS. With the exception of very severe cases, hypersomnia is often unrecognized in clinical practice. Actigraphy allows to detect changes of sleep/rest needs in stroke patients, but may have limited use in patients with severe motor deficits. Sleep questionnaires (e.g., Epworth Sleepiness Scale, Fatigue Severity Scale), which evaluate EDS and fatigue, may underestimate SWD in stroke patients with disturbed self-perception or communication skills. Polysomnography, multiple sleep latency tests, and maintenance of wakefulness tests are reserved for selected cases. The correlation of poststroke SWD and sleep EEG is limited when brain damage includes thalamo-cortical networks. Polysomnography typically reveals a reduction, less commonly an increase of NREM or REM sleep.

Treatment of poststroke hypersomnia/EDS is challenging (table 2). In patients with paramedian thalamic stroke, improvement of sleep patterns was reported with 20–40 mg bromocriptine, 200 mg modafinil, or 20–50 mg methylphenidate (Class IV evidence). A favorable effect on early stroke recovery was observed after levodopa (100 mg/d) or methylphenidate (5–30 mg/d), which may at least partly be related to improved wakefulness. Stimulating antidepressants may also improve hypersomnia. Whether treatment of hypersomnia, EDS, or fatigue improves stroke outcome and recurrent risk needs to be shown.

Insomnia/reduced sleep. The presence of insomnia is often overlooked in clinical practice. Questionnaires and actigraphy can be useful to recognize insomnia,

### Table 2  
Diagnostics and treatment of sleep-related breathing and sleep-wake disorders following stroke

<table>
<thead>
<tr>
<th>Sleep-wake disorder</th>
<th>Diagnostics</th>
<th>Avoid/use with cautions</th>
<th>Treatment</th>
<th>Level of evidence/recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Obstructive sleep apnea</strong></td>
<td>History, respirography (polysomnography)</td>
<td>Alcohol, hypnotics, sedative antidepressants</td>
<td>CPAP</td>
<td>IIb, B</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transnasal high-flow air insufflation</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Preventing supine sleeping position with therapeutic pillow</td>
<td>III, C²</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Weight loss</td>
<td>IV, U</td>
</tr>
<tr>
<td><strong>Central sleep apnea/ Cheyne-Stokes breathing</strong></td>
<td>History, respirography (polysomnography)</td>
<td>Alcohol, hypnotics, sedative antidepressants</td>
<td>CPAP/biphasic positive airway pressure</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adaptive servoventilation</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oxygen</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tracheotomy/mechanical ventilation in severe central apnea</td>
<td>IV, U</td>
</tr>
<tr>
<td><strong>Disturbances of wakefulness (hypersomnia, EDS, fatigue)</strong></td>
<td>History, questionnaires (actigraphy, polysomnography, vigilance tests)</td>
<td>Alcohol, hypnotics, sedative antidepressants</td>
<td>Stimulating antidepressants (e.g., venlafaxine 37.5-150 mg/d)</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Simulants: modafinil (100-200 mg/d), methylphenidate (5-60 mg/d)</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Levodopa (125-250 mg/d)</td>
<td>IV, U</td>
</tr>
<tr>
<td><strong>Insomnia</strong></td>
<td>History (questionnaires, actigraphy, polysomnography)</td>
<td>Alcohol, caffeine, stimulating antidepressants</td>
<td>Zolpidem, zopiclone</td>
<td>IV, L⁶</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sedative antidepressants (amitriptyline 10-100 mg/d; trazodone 50-200 mg/d; mianserin 60 mg/d; mirtazapine 15-30 mg/d)</td>
<td>IV, U (mianserin: III, C⁷)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nonpharmacologic sleep hygiene (avoid noises, treat infections, avoid alcohol and caffeine at night)</td>
<td>IV, U</td>
</tr>
<tr>
<td><strong>Restless legs syndrome/ periodic limb movements during sleep</strong></td>
<td>History, polysomnography</td>
<td>Antidepressants, neuroleptics, metoclopramide, lithium</td>
<td>Levodopa (125-250 mg at night)</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dopamine agonists (ropinirole 0.25-1 mg/d; pramipexole 0.125-0.75 mg/d)</td>
<td>III, U</td>
</tr>
<tr>
<td><strong>REM sleep behavior disorder</strong></td>
<td>History, polysomnography</td>
<td>Alcohol, antidepressants (serotonin reuptake inhibitors), stimulants, selegiline</td>
<td>Gabapentin (150-300 mg/d)</td>
<td>IV, U</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clonazepam (0.5-2 mg at night)</td>
<td>IV, U</td>
</tr>
</tbody>
</table>

Abbreviations: CPAP = continuous positive airway pressure; EDS = excessive daytime sleepiness.

Recommendations based on American Academy of Neurology classification of recommendation. Only studies in stroke patients were considered.

- Refers to effects on apnea-hypopnea index or sleep, not stroke outcome.
- Beneficial effect on stroke outcome and recurrent stroke risk unlikely.
but may underestimate SWD (see above). Polysomnography is mainly used for detecting secondary insomnias (e.g., related to SDB or RLS/PLMS).

Treatment of poststroke insomnia includes placement of patients in quiet rooms at night, protection from noise and light, light exposure and physical activity during the day, and, where necessary, temporary use of hypnotics that are relatively free of cognitive and muscle-relaxant effects, such as zolpidem, which in a small study of 12 stroke patients had similar effects on total sleep time and sleep quality as lorazepam\(^2\) and may have beneficial effects on stroke recovery based on experimental stroke studies.\(^5\) Benzodiazepines may worsen SDB and neuropsychological deficits and lead to reemergence of motor deficits (table 2). Sedative antidepressants may improve poststroke insomnia (table 2). In 51 stroke patients, 60 mg/d mianserin improved insomnia, also in patients without depression (Class III evidence).\(^2\)

In case-control studies, hypnotics elevated stroke risk. In 12,747 ischemic stroke patients matched with participants without stroke, zolpidem use was dose-dependently associated with ischemic stroke risk (OR 1.50 for >470 mg zolpidem/y).\(^7\)

In a cohort of 38,671 patients on benzodiazepines matched with patients without benzodiazepines, a high annual benzodiazepine dose (\(\geq 4\) g) or long duration of benzodiazepine use (\(\geq 95\) days) increased stroke incidence.\(^5\) Further studies are needed to delineate effects of hypnotics on stroke recovery and recurrence.

**RLS/PLMS.** RLS is a clinical diagnosis, while PLMS diagnosis requires polysomnography. RLS symptoms are often not perceived by stroke patients.

Patients with stroke-related RLS/PLMS can be treated with dopamine agonists (ropinirole 0.25–1 mg/d, pramipexole 0.125–0.5 mg/d) or gabapentin (150–300 mg/d) (table 2). Using dopamine agonists, Lee et al.\(^13\) reported marked relief in almost all patients. Spontaneous improvement was noted in approximately 1 of 4 patients.\(^13\) Antidepressants, neuroleptics, metoclopramide, and lithium should be avoided wherever possible, because they may aggravate RLS/PLMS. Whether RLS/PLMS treatment influences stroke outcome or recurrence needs to be shown.

**REM sleep behavior disorder.** RBD can be suspected on clinical grounds but diagnosis requires videopolysomnography. Clonazepam at bedtime efficiently improves RBD. Although Class IV evidence, stroke patients with RBD may receive clonazepam (0.5–2.0 mg) (table 2). Alcohol, serotonin reuptake inhibitors, stimulants, and selegiline aggravate RBD. They should be avoided in RBD.

**FUTURE DIRECTIONS AND RECOMMENDATIONS**

Systematic approaches for the diagnosis and treatment of SDB and SWD should be implemented in the management of stroke and TIA. Oximetry or nasal flow measurement can suggest SDB, which should be confirmed by respirography before treatment. Careful patient histories, questionnaires, and actigraphies improve the detection of SWD. Treatment is relevant for stroke recovery and outcome, but should be used thoughtfully considering potential side effects.

**AUTHOR CONTRIBUTIONS**

D.M.H., C.L.B.: study concept and design, acquisition of data and articles, analysis and interpretation, critical revision of the manuscript for important intellectual content, study supervision. D.M.H.: drafting of manuscript.

**STUDY FUNDING**

No targeted funding reported.

**DISCLOSURE**

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received December 27, 2015. Accepted in final form June 9, 2016.

**REFERENCES**

Role of sleep-disordered breathing and sleep-wake disturbances for stroke and stroke recovery
Dirk M. Hermann and Claudio L. Bassetti
Neurology published online August 3, 2016
DOI 10.1212/WNL.0000000000003037

This information is current as of August 3, 2016